Martin Weltman

Dr. Martin Weltman

Nepean Hospital, Sydney, Australia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2024 in Hepatology
Verified
Journal Article
Open access
DJDavid E.J. Jones
David E.J. Jones
UBUlrich Beuers
Ulrich Beuers
ABAlan Bonder
Alan Bonder
Marco CarboneMarco Carbone
Marco Carbone
ECEmma L Culver
Emma L Culver
CLCynthia Levy
Cynthia Levy
Primary biliary cholangitis (PBC) is a chronic cholestatic liver disease. The management landscape was transformed 20 years ago with the advent of ursodeoxycholic acid. Up to 40% of patients do not, however, respond adequately to ursodeoxycholic acid and therefore still remain at risk of disease progression to cirrhosis. The introduction of obeticholic acid as a second-line therapy for patients failing ursodeoxycholic acid has improved outcomes for patients with PBC. There remains, however, a need for better treatment for patients at higher risk. The greatest threat facing our efforts to improve treatment in PBC is, paradoxically, the regulatory approval model providing conditional marketing authorization for new drugs based on biochemical markers on the condition that long-term, randomized placebo-controlled outcome trials are performed to confirm efficacy. As demonstrated by the COBALT confirmatory study with obeticholic acid, it is difficult to retain patients in the required follow-on confirmatory placebo-controlled PBC outcome trials when a licensed drug is commercially available. New PBC therapies in development, such as the peroxisome proliferator–activated receptor agonists, face even greater challenges in demonstrating outcome benefit through randomized placebo-controlled studies once following conditional marketing authorization, as there will be even more treatment options available. A recently published EMA Reflection Paper provides some guidance on the regulatory pathway to full approval but fails to recognize the importance of real-world data in providing evidence of outcome benefit in rare diseases. Here we explore the impact of the EMA reflection paper on PBC therapy and offer pragmatic solutions for generating evidence of long-term outcomes through real-world data collection.

4 May 2023 in Metabolism
Verified
Journal Article
Closed access
JAJawaher Alharthi
Jawaher Alharthi
ZPZiyan Pan
Ziyan Pan
BGBrian S. Gloss
Brian S. Gloss
DMDuncan McLeod
Duncan McLeod
MWMartin Weltman
Martin Weltman
MEMohammed Eslam
Mohammed Eslam

7 November 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
GWGrace Lai-Hung Wong
Grace Lai-Hung Wong
MYMan-Fung Yuen
Man-Fung Yuen
BLBing-Liang Lin
Bing-Liang Lin
Mark William DouglasMark William Douglas
Mark William Douglas
PHPeng Hu
Peng Hu
ZHZhi Hong
Zhi Hong
Functional cure is a goal for the treatment of chronic hepatitis B virus (HBV) infection; however, it is infrequently achieved with currently approved treatments. Here we provide a randomized evaluation of the small interfering RNA elebsiran, in combination with pegylated interferon alfa (PEG-IFNα), compared with PEG-IFNα monotherapy. In addition, this study evaluates the potential role of the HBV therapeutic vaccine BRII-179 in identifying immunologically responsive patients and improving hepatitis B surface antigen (HBsAg) loss rates. In part I (cohorts 1–3), virally suppressed participants with chronic HBV infection naive to BRII-179 were randomized 1:1:1 to receive 48 weekly doses of PEG-IFNα alone or in combination with 13 doses of elebsiran (200 mg or 100 mg) administered every 4 weeks. In part II (cohort 4), participants who had previously received 9 doses of elebsiran and BRII-179 in a prospective study (BRII-179-835-001) were categorized as BRII-179 anti-HBs responders or nonresponders based on their peak hepatitis B surface antibody (anti-HBs) levels (≥10 IU l−1 or <10 IU l−1, respectively) and subsequently received 13 doses of elebsiran 100 mg every 4 weeks plus 48 weekly doses of PEG-IFNα. Primary endpoints were HBsAg loss at the end of treatment (EOT) and 24 weeks post-EOT. In part I, at 24 weeks post-EOT, HBsAg loss was observed in 4 out of 19 (21.1%) participants receiving elebsiran 200 mg plus PEG-IFNα, 6 out of 18 (33.3%) participants receiving elebsiran 100 mg plus PEG-IFNα and 1 out of 18 (5.6%) participants receiving PEG-IFNα monotherapy. In part II, HBsAg loss was observed in 9 out of 31 (29.0%) participants at 24 weeks post-EOT, with a higher response among BRII-179 anti-HBs responders (8 out of 19 participants, 42.1%) compared with nonresponders (1 out of 12 participants, 8.3%). Elebsiran and PEG-IFNα combination therapy was generally safe and well tolerated. These results demonstrate an additive benefit of elebsiran when combined with PEG-IFNα in achieving sustained HBsAg loss. Furthermore, the increased HBsAg loss rate in BRII-179 anti-HBs responders suggests that BRII-179 may be a valuable tool for immunological profiling to optimize curative outcomes in patients with HBV infection. ClinicalTrials.gov registration: NCT05970289.

25 March 2017 in Clinical and Molecular Hepatology
Verified
Journal Article
Open access
PDF file
ACAngela Cropley
Angela Cropley
MWMartin Weltman
Martin Weltman
Autoimmune hepatitis (AIH) is an organ specific autoimmune condition which can manifest at any age of life. The heterogeneous nature of this condition means that great variation can be seen in severity, progression of disease and response to treatment within this patient group. Since the 1980s prednisolone and azathioprine have been used for induction and remission of the disease and remain the mainstay of treatment. Other immunosuppressive agents have been employed in difficult to treat cases. While there is less published data regarding these agents compared with the conventional treatments of steroid and azathioprine, there is mounting evidence to support the use of mycophenolate mofetil as a second-line agent. The calcineurin inhibitors, though less studied, additionally show promise. More data is needed on the use of biological agents in refractory disease. This review focuses on our centre's approach to treatment of AIH in the context of a contemporary review of the literature.

9 March 2022 in Hepatobiliary & Pancreatic Diseases International
Verified
Journal Article
Closed access
HJHydar El Jamaly
Hydar El Jamaly
GEGuy D Eslick
Guy D Eslick
MWMartin Weltman
Martin Weltman

15 August 2021 in Scandinavian Journal of Gastroenterology
Verified
Journal Article
Closed access
HJHydar El Jamaly
Hydar El Jamaly
GEGuy D. Eslick
Guy D. Eslick
MWMartin Weltman
Martin Weltman
Maternal and fetal outcomes in pregnant patients with autoimmune hepatitis (AIH) has been largely unexplored.This meta-analysis aims to determine the level of evidence associated with both maternal...